Table 3.
Relationship between the results of ANCA testing and clinical diagnoses.
| Diseases | p-ANCA | c-ANCA | x-ANCA | IIF (−)/ELISA (+) | Anti-MPO (+) | Anti-PR3 (+) | Total (N) | |
|---|---|---|---|---|---|---|---|---|
| MPA | N | 45 | 4 | 6 | 6 | 46 | 10 | 61 |
| % | 73.8 | 6.6 | 9.8 | 9.8 | 75.4 | 16.4 | ||
| WG | N | 6 | 34 | 1 | 5 | 4 | 40 | 46 |
| % | 13.0 | 73.9 | 2.2 | 10.9 | 8.7 | 87 | ||
| CSS | N | 4 | 0 | 2 | 0 | 6 | 0 | 6 |
| % | 66.7 | 0.0 | 33.3 | 0.0 | 100 | 0.0 | ||
| CTD | N | 97 | 2 | 31 | 2 | 9 | 1 | 132 |
| % | 73.5 | 1.5 | 23.5 | 1.5 | 6.8 | 0.7 | ||
| GD | N | 67 | 10 | 40 | 0 | 1 | 8 | 117 |
| % | 57.3 | 8.5 | 34.2 | 0.0 | 17.9 | 7.7 | ||
| Other vasculitides | N | 27 | 1 | 11 | 0 | 7 | 3 | 39 |
| % | 69.2 | 2.6 | 28.2 | 0.0 | 5.6 | 0.0 | ||
| Infections | N | 23 | 1 | 12 | 0 | 2 | 0 | 36 |
| % | 63.9 | 2.8 | 33.3 | 0.0 | 5.6 | 0.0 | ||
| ND | N | 23 | 1 | 9 | 0 | 0 | 0 | 33 |
| % | 69.7 | 3.0 | 27.3 | 0.0 | 0.0 | 0.0 | ||
| Malignancies | N | 21 | 1 | 9 | 0 | 1 | 0 | 31 |
| % | 67.7 | 3.3 | 29.0 | 0.0 | 3.3 | 0.0 | ||
| RD | N | 18 | 0 | 4 | 0 | 2 | 0 | 22 |
| % | 81.8 | 0.0 | 18.2 | 0.0 | 9.0 | 0.0 | ||
| Medication | N | 10 | 0 | 5 | 0 | 0 | 0 | 15 |
| % | 66.7 | 0.0 | 33.3 | 0.0 | 0.0 | 0.0 | ||
| Miscellaneous disorders | N | 5 | 2 | 6 | 1 | 0 | 1 | 14 |
| % | 35.7 | 14.3 | 42.9 | 7.1 | 0.0 | 7.1 | ||
| Undefined diagnosis | N | 63 | 4 | 39 | 3 | 2 | 3 | 109 |
| % | 57.8 | 3.7 | 35.8 | 2.7 | 1.8 | 2.7 | ||
MPA: microscopic polyangiitis, WG: Wegener's granulomatosis, CSS: Churg-Strauss syndrome, CTD: connective tissue diseases, GD: gastrointestinal diseases, ND: neurological diseases, RD: renal diseases.